Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Kinetically guided neoadjuvant chemoradiotherapy based on 5-Fluorouracil in patients with locally advanced rectal cancer

J. Grim, M. Hroch, H. Miloš, J. Chládek, C. Jaroslav, J. Petera, P. Jiří, J. Martínková, M. Jiřina,

. 2015 ; 54 (5) : 503-15.

Jazyk angličtina Země Nový Zéland

Typ dokumentu klinické zkoušky, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16010662
E-zdroje Online Plný text

NLK ProQuest Central od 2007-06-01 do Před 1 rokem
Health & Medicine (ProQuest) od 2007-06-01 do Před 1 rokem

BACKGROUND AND PURPOSE: This study estimated patients' early response following neoadjuvant chemoradiotherapy (CHRT) of locally advanced rectal cancer based on 5-fluorouracil (5-FU). The target was to achieve pathological complete response (pCR; residual disease-free stage) and toxicities of grade ≤2, using individual dosing predicted according to the steady-state plasma concentration (C ss) and pharmacokinetic parameters of 5-FU: the area under the time-concentration curve at steady state (AUC) and clearance (CL). PATIENTS AND METHODS: This open-label prospective study enrolled 33 adult patients treated with 5-FU administered as a continuous intravenous infusion over 4-5 weeks, as follows: in Group 1a (N = 6), the patients received a standard dose of 300 mg/m(2)/24 h. In Group 1b (N = 7), the patients were treated with an escalated dose of 400-1,000 mg/m(2)/24 h. In Group 2 (N = 20), the patients were given dosing kinetically guided in order to reach the target range of 5-FU C ss 50-100 µg/L. Tolerability was tested according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Radiotherapy was delivered with 10-15 MV photon beams at 1.8 Gy/fraction up to 50.4 Gy in 28 daily fractions for 5 days a week. Surgery followed 4-6 weeks after the completion of CHRT and clinical restaging. The pCR and residual tumour stage were evaluated using preoperative tumour downstaging in magnetic resonance, postoperative histopathological staging and tumour regression rate (residual disease). RESULTS AND CONCLUSION: The cumulative AUC of 5-FU (total exposure to the drug) correlated with cumulative 5-FU dose (r = 0.61; p < 0.001) and residual disease (r s = -0.53; p < 0.005). A higher target pCR rate was reached in patients individually treated (Group 2) who finished the whole 5-week CHRT. The individual daily dose needed to reach the target C ss should be >350 mg/m(2) (up to 600 mg/m(2)) provided that 5-FU metabolic ratio is within the range of 2.5-6 and the cumulative AUC5wks is within 50-100 mg·h/L.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16010662
003      
CZ-PrNML
005      
20171219080826.0
007      
ta
008      
160408s2015 nz f 000 0|engg|
009      
AR
024    7_
$a 10.1007/s40262-014-0216-4 $2 doi
024    7_
$a 10.1007/s40262-014-0216-4 $2 doi
035    __
$a (PubMed)25503423
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a nz
100    1_
$a Grim, Jiří $u Department of Oncology and Radiotherapy, University Hospital, Sokolská Street, 500 05, Hradec Králové, Czech Republic, grimj@lfhk.cuni.cz.
245    10
$a Kinetically guided neoadjuvant chemoradiotherapy based on 5-Fluorouracil in patients with locally advanced rectal cancer / $c J. Grim, M. Hroch, H. Miloš, J. Chládek, C. Jaroslav, J. Petera, P. Jiří, J. Martínková, M. Jiřina,
520    9_
$a BACKGROUND AND PURPOSE: This study estimated patients' early response following neoadjuvant chemoradiotherapy (CHRT) of locally advanced rectal cancer based on 5-fluorouracil (5-FU). The target was to achieve pathological complete response (pCR; residual disease-free stage) and toxicities of grade ≤2, using individual dosing predicted according to the steady-state plasma concentration (C ss) and pharmacokinetic parameters of 5-FU: the area under the time-concentration curve at steady state (AUC) and clearance (CL). PATIENTS AND METHODS: This open-label prospective study enrolled 33 adult patients treated with 5-FU administered as a continuous intravenous infusion over 4-5 weeks, as follows: in Group 1a (N = 6), the patients received a standard dose of 300 mg/m(2)/24 h. In Group 1b (N = 7), the patients were treated with an escalated dose of 400-1,000 mg/m(2)/24 h. In Group 2 (N = 20), the patients were given dosing kinetically guided in order to reach the target range of 5-FU C ss 50-100 µg/L. Tolerability was tested according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Radiotherapy was delivered with 10-15 MV photon beams at 1.8 Gy/fraction up to 50.4 Gy in 28 daily fractions for 5 days a week. Surgery followed 4-6 weeks after the completion of CHRT and clinical restaging. The pCR and residual tumour stage were evaluated using preoperative tumour downstaging in magnetic resonance, postoperative histopathological staging and tumour regression rate (residual disease). RESULTS AND CONCLUSION: The cumulative AUC of 5-FU (total exposure to the drug) correlated with cumulative 5-FU dose (r = 0.61; p < 0.001) and residual disease (r s = -0.53; p < 0.005). A higher target pCR rate was reached in patients individually treated (Group 2) who finished the whole 5-week CHRT. The individual daily dose needed to reach the target C ss should be >350 mg/m(2) (up to 600 mg/m(2)) provided that 5-FU metabolic ratio is within the range of 2.5-6 and the cumulative AUC5wks is within 50-100 mg·h/L.
650    _2
$a senioři $7 D000368
650    _2
$a protinádorové antimetabolity $x aplikace a dávkování $x škodlivé účinky $x farmakokinetika $7 D000964
650    _2
$a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $x terapeutické užití $7 D000971
650    _2
$a chemoradioterapie $7 D059248
650    _2
$a kombinovaná terapie $7 D003131
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fluoruracil $x aplikace a dávkování $x škodlivé účinky $x farmakokinetika $7 D005472
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a intravenózní infuze $7 D007262
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a neoadjuvantní terapie $7 D020360
650    _2
$a staging nádorů $x metody $7 D009367
650    _2
$a prospektivní studie $7 D011446
650    _2
$a nádory rekta $x farmakoterapie $x metabolismus $x patologie $x radioterapie $7 D012004
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Hroch, Miloš, $d 1976- $7 xx0076212
700    1_
$a Chládek, Jaroslav
700    1_
$a Petera, Jiří
700    1_
$a Martínková, Jiřina
773    0_
$w MED00001154 $t Clinical pharmacokinetics $x 0312-5963 $g Roč. 54, č. 5 (2015), s. 503-15
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25503423 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160408 $b ABA008
991    __
$a 20171219081022 $b ABA008
999    __
$a ok $b bmc $g 1114091 $s 935030
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 54 $c 5 $d 503-15 $i 0312-5963 $m Clinical pharmacokinetics $n Clin Pharmacokinet $x MED00001154
LZP    __
$a Pubmed-20160408

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...